Initial Forecasts. Not less than six months prior to the date of the first anticipated delivery of any Product by Gen-Probe to Chiron, Chiron shall prepare and provide Gen-Probe with a written forecast of the estimated requirements of Chiron and its Affiliates for each Blood Screening Assay, Blood Screening Instrument, Clinical Diagnostic Assay, Clinical Diagnostic Instrument, or Rare Reagent for each of the twelve (12) calendar months beginning with the month of the first anticipated delivery of any Product. Gen-Probe shall respond to Chiron's forecast in writing within thirty (30) days and shall have no obligation with respect to such forecast unless it has approved such forecast in writing. Gen-Probe shall use Commercially Reasonable Efforts to meet the market demand for the Products as to which it has undertaken an obligation to manufacture. Not less than three months prior to the date of the first anticipated delivery of any Product, Chiron shall prepare and provide Gen-Probe with a more current written forecast covering the same Products and period. Gen-Probe shall respond to Chiron's updated forecast in writing within ten (10) days. Gen-Probe shall have no obligation with respect to such updated forecast to the extent that the forecasted quantity of any Product has been increased by more than fifteen percent (15%) for the first three-month period of such forecast, or by more than twenty-five percent (25%) for the twelve-month period of such forecast, from the previously-approved amount for such Product unless it has approved such increase in writing. The parties recognize that forecasting the first year for any Product will be difficult and that actual experience may significantly vary from the forecast. Without modifying any other provision of this Agreement, the parties agree to work together to address the first year supply of Products, and to use Commercially Reasonable Efforts to satisfy the market need.
Initial Forecasts. At least [***] months prior to the estimated initial launch date of Licensed Product for the Initial Indication in the Territory (the “Launch Date”) or within [***] days after the Effective Date, whichever is later, Orion shall furnish to Indevus a written forecast of its estimated requirements for Bulk Drug Product for the *** CONFIDENTIAL TREATMENT REQUESTED eight (8) Calendar Quarters (broken down by Calendar Quarter) commencing with the Calendar Quarter in which the Launch Date is estimated to occur (even if such Calendar Quarter is less than a complete Calendar Quarter) (the “Initial Forecast”). On June 30, 2008, Orion shall provide Indevus with an updated Initial Forecast.
Initial Forecasts. Within [**] days of the Effective Date, the CT shall provide to the ST both a Rolling Monthly Forecast and a [**]-Year Forecast of expected Product Requirements and Placebo Requirements.
Initial Forecasts. On or before the [ ]* of the calendar quarter, beginning at least [ ]* prior to the anticipated Commencement Date, Cubist shall furnish to Cardinal Health a written [ ]* rolling forecast of the quantities of Product that Cubist intends to order from Cardinal Health during the [ ]* period commencing with the start of the next calendar quarter (“Initial Forecast”). The first [ ]* of such Initial Forecast shall constitute a binding commitment for the quantities of Product specified therein (“Firm Commitment”) and the following [ ]* of the Initial Forecast shall be non-binding, good faith estimates (“Estimated Commitment”).
Initial Forecasts. As of the date of receipt by Rhein Biotech and GCVC of notice of the first regulatory approval for the Product, Rhein Biotech and GCVC shall provide non-binding estimates for deliveries of the Bulk Chiron Material for a twelve (12) month period divided on a quarterly basis and for one subsequent twelve (12) month period to meet the Parties’ estimated Contract Requirements for each Product, in accordance with the terms of the Collaboration Agreement and the Collaboration and Development Plan.
Initial Forecasts. As of the date of receipt by Chiron of notice of the first regulatory approval for the Product, Chiron shall provide non-binding estimates for deliveries of the Product for a twelve (12) month period divided on a quarterly basis and for one subsequent twelve (12) month period to meet the estimated Chiron Contract Requirements for each Product, in accordance with the terms of the Collaboration Agreement and the Collaboration and Development Plan.
Initial Forecasts. TRUNKING REQUIREMENTS Because BA's trunking requirements will, at least during an initial period, be dependent on the customer segments and service segments within customer segments to whom ACI decides to market its services, BA will be largely dependent on ACI to provide accurate trunk forecasts for both inbound (from BA) and outbound (from ACI) traffic. BA will, as an initial matter and upon request, provide the same number of trunks to terminate local traffic to ACI as ACI provides to terminate local traffic to BA, unless ACI expressly identifies particular situations that are expected to produce traffic that is substantially skewed in either the inbound or outbound direction, in which case BA will provide the number of trunks ACI suggests; provided, however, that in all cases BA's provision of the forecasted number of trunks to ACI is conditioned on the following: that such forecast is based on reasonable engineering criteria, there are no capacity constraints, and ACI's previous forecasts have proven to be reliable and accurate.
Initial Forecasts. 4.2.1 AstraZeneca’s current forecast for Packed Tablets as of the Execution Date, on a SKU-by-SKU basis (“AstraZeneca Forecast”) is attached hereto as Schedule 1.
Initial Forecasts. The Monthly Declarations for the Months of September and October, 1999 are attached as Exhibit A hereto. The Quarterly Forecast for the calendar quarter ending December 31, 1999 is attached as Exhibit B hereto.
